Trial Profile
A Phase I Study to Determine the Safety of Imatinib in Combination With PTK787/ZK222584 in Patients With Refractory and/or Advanced Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2013
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Vatalanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 28 Apr 2011 Planned End Date changed from 1 Jan 2009 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2008 New trial record.